Talking Ketamine Podcast

In episode 53, we move out of the sterile lab and into the messy real world, examining a large naturalistic study of 224 patients from an Austin clinic. The paper by Kosted and colleagues compares standard “infusion-only” ketamine treatment against Ketamine-Assisted Therapy (KAT) to answer a costly question: is paying for a therapist to be in the room actually worth it?

The average results were shocking: across the entire sample, the therapy group didn’t fare any better than the infusion-only group. But when researchers sliced the data by age and Adverse Childhood Experiences (ACEs), a much more complex story emerged. We unpack the counterintuitive “super responder” effect, where patients with high childhood trauma saw the most dramatic biological healing. For young adults under 30, the medicine alone was often more effective, suggesting that talk therapy might actually interrupt the “bake” of neuroplasticity by shifting activity to the analytical brain too soon. Conversely, for patients over 50, therapy was essential; without a human connection to help navigate and rewire decades of compensatory behaviors, the ketamine alone often fell short.

Finally, we discuss the practical implications of the “decelerating curve” of improvement—where the most dramatic drops in depression occur early in treatment—and why the future of personalized psychiatry must look beyond DNA to a patient’s lived biography.

Reference:

Kosted, R., Waddell, A., Adolph, K., & Fonzo, G. A. (2026). Age-related moderation of adjunctive psychotherapy and early life stress effects on depression symptom reductions following ketamine treatment: Initial insights from a large, naturalistic sample. Journal of Affective Disorders, 402, 121350. https://doi.org/10.1016/j.jad.2026.121350

For the podcast’s one-year anniversary, we zoom out from single studies to examine a comprehensive masterpiece: the doctoral thesis of Jolien K.E. Veraart, representing nine years of research (2016–2026) at the University of Groningen. This document moves beyond the initial hype of “does it work?” to the mature, difficult questions of long-term maintenance and safety.

We unpack the critical concept of auto-induction—the discovery that the liver eventually “learns” to metabolize ketamine so efficiently that stable doses stop working, creating a bioavailability trap that looks like relapse but is actually just enzymatic efficiency. The episode also tackles the “nightmare” of oral dosing, where absorption is so variable that it makes consistent treatment a roll of the dice.

Finally, we discuss the philosophical shift in Veraart’s work: moving away from the “trip” as the cure and toward a model where ketamine simply “softens the clay” of the brain. This places the responsibility back on set and setting not just as a safety measure, but as the tool that sculpts the neuroplastic brain into a healthier shape.

Reference:

Veraart, J. K. E. (2026). Ketamine for depression: Moving from research to clinical practice [Doctoral thesis, University of Groningen]. https://doi.org/10.33612/diss.1484805904

In the world of ketamine therapy, there is a distinct divide: the FDA-approved, insurance-covered “Gold Standard” (Esketamine/Spravato) versus the cheap, off-label generic (Racemic Ketamine). In this episode, we step into the ring to judge “The Nasal Spray Wars” using a groundbreaking 2026 meta-analysis by Bahji and colleagues published in the Journal of Affective Disorders.

We break down the “skim milk vs. whole milk” pharmacology: Esketamine isolates just the S-isomer, while generic ketamine contains both the S and R isomers. Big Pharma argues the isolate is cleaner, but the data tells a different story. We reveal the study’s stunning conclusion: there is no significant difference in symptom relief between the two. In fact, the “cheap” generic showed higher remission rates and lower dropout rates than its expensive counterpart.

The discussion tackles the massive elephant in the room: accessibility. With Spravato costing thousands of dollars per month and requiring strict in-clinic monitoring, we ask if the “premium” price tag is buying better health or just a patent. We conclude with a verdict for patients paying out-of-pocket: choosing the generic isn’t “settling”—it may actually be the more effective, and certainly the more sustainable, path to recovery.

Reference:

Sarlon, J., Thomi, D., Brühl, A. B., Liwinski, T., & Lang, U. E. (2026). Real-world comparison of intranasal racemic ketamine and esketamine in treatment-resistant depression: A retrospective observational study. Journal of Affective Disorders, 400, 121208. https://doi.org/10.1016/j.jad.2026.121208

For decades, we’ve imagined the synapse as a “chemical soup”—a messy place where one neuron sprays neurotransmitters at another, hoping for a connection. But in this milestone 50th episode, we use the lens of the groundbreaking book Nano-Organization of the Synapse to reveal the stunning reality: the synapse is actually a piece of high-precision Swiss watchmaking.

We explore the revolution in super-resolution microscopy (like STORM and cryo-electron tomography) that has allowed us to see the nanocolumn—a dedicated architectural alignment where a presynaptic “launch pad” (controlled by the protein Munc13) sits perfectly opposite a postsynaptic “receiver slot” (held by PSD95). This “trans-synaptic alignment” ensures that every signal is a sniper shot, not a sprinkler spray.

The episode dives into the three modes of transmission—synchronous (the fast lane), asynchronous (the stutter), and the critical spontaneous release (the “ghost in the machine”). We discuss the theory that depression is a failure of this nanoscopic geometry, where the “ghost” signal reinforces a broken state. Finally, we explain how ketamine acts as a rapid repair crew: by silencing the spontaneous noise at NMDA receptors, it triggers a panic-like “homeostatic plasticity” that forces the neuron to realign its columns, add more AMPA receptors (volume knobs), and restore the “liquid crystal” dance of the synapse.

Reference:

Kavalali, E. T. (Ed.). (2026). Nano-organization of the synapse: From structure to function (Vol. 48). Springer Nature Switzerland. https://doi.org/10.1007/978-3-032-12594-1

For decades, the “Monoamine Dogma” ruled psychiatry: the brain was a chemical soup, depression was a lack of serotonin, and the cure was simply “filling the tank.” But there was always a glitch in the matrix—why did it take weeks for pills to work if the chemistry changed in hours?

In this special 25th-anniversary episode, we review a retrospective paper from 2026 that traces the history of the “Neuroplastic Revolution.” We go back to the turning point: the accidental discovery that ketamine could stop depression in four hours, proving the problem wasn’t a lack of fuel, but broken wiring.

We unpack the science of structural repair: how ketamine blocks the “disappointment center” (the lateral habenula), wakes up the “construction foreman” (mTOR), and releases BDNF (Miracle-Gro for the brain) to physically regrow lost connections. We also look at the macro level, exploring how this “reboot” disrupts the Default Mode Network to stop the loop of rumination. Finally, we discuss where we are today in 2026: the age of Precision Psychiatry, where we stop guessing and start treating the specific biological cause—whether it’s inflammation, glutamate, or connectivity.

Reference:

Bulek, D., & BaDour, S. (2026). From monoamine deficits to multiscale plasticity: Twenty-five years of ketamine and the neurophysiology of depression. Journal of Neurophysiology. https://doi.org/10.1152/jn.00516.2025

Patients with diabetes often face a brutal “syndemic”—a tangled web of chronic illness, Relentless nerve pain (neuropathy), and severe depression, all fueled by a common biological enemy: metabolic inflammation and Advanced Glycation End-products (AGEs). In this episode, we explore why ketamine, with its rapid antidepressant and non-opioid painkilling properties, looks like the perfect “two birds, one stone” solution on paper.

But in practice, it requires walking a high-stakes “metabolic tightrope.” We dive into the complex risks:

* The Glucose Rollercoaster: Ketamine can trigger a stress response that spikes blood sugar (hyperglycemia), yet in Type 1 diabetics, it has also been linked to dangerous, delayed drops (hypoglycemia).

* The Liver “Traffic Jam”: In Type 2 diabetes, fatty liver disease can clog the body’s filter, slowing down drug clearance and potentially turning a normal dose toxic.

* The Metformin Paradox: We discuss preclinical warnings that metformin—the most common diabetes drug—might actually blunt ketamine’s antidepressant effects.

The solution? A move away from “one-size-fits-all” medicine toward Model-Informed Precision Dosing—using a patient’s kidney function, liver health, and genetics to calculate the perfect, safe dose.

Reference:

Sukhram, S. D., Sanchez, M., Anidugbe, A., Kupa, B., Edwards, V. P., Zia, M., & Yilmaz, G. (2026). Ketamine in diabetes care: Metabolic insights and clinical applications. Pharmaceutics, 18(1), 81. https://doi.org/10.3390/pharmaceutics18010081

For most individuals entering a ketamine clinic, the drug is not a first-line choice; it is a "last resort" born out of years of therapeutic failure and profound desperation. This episode shifts the focus from receptors and clinical protocols to the "lived experience" of the person in the chair. We explore the complex emotional landscape of Treatment-Resistant Depression (TRD), where a tiny flicker of anticipatory hope must battle against the heavy memory of repeated disappointments.

During the acute session, patients describe a "rapid roller-coaster" of consciousness. This isn't just a simple high; it is a profound disruption of reality where "hands feel backwards" and one might feel as though they are "floating in an empty void." However, the most striking transformation often occurs in the hours and days that follow. Using the powerful analogy of "lifting the blanket," patients describe a shift from paralyzed negativity to a lighter, more neutral mood—a space where overwhelming worries finally feel like concrete, solvable tasks.

We dive into a comprehensive narrative review by Walaszek and colleagues to address the "measurement mismatch" in modern psychiatry. While clinicians often obsess over dissociation metrics like the CADSS, patients define their recovery through social connection, personal agency, and the quality of the therapeutic alliance. Ultimately, we discuss why the "psychosocial container"—the sense of being safe and "looked after"—is not just a comfort, but a core mechanism that may account for up to 50% of the therapeutic benefit.

Resources:

Walaszek, M., Cubała, W. J., & Kachlik, Z. (2026). Patients’ voices on ketamine for treatment-resistant depression: A narrative review of qualitative perspectives. Journal of Clinical Medicine, 15(1), 150. https://doi.org/10.3390/jcm15010150.

Ketamine, initially hailed as a safer anesthetic in the 1960s, came with a peculiar side effect: a feeling of sensory detachment and altered perception known as dissociation. For decades, this "K-hole" experience was largely viewed as an unwanted nuisance. However, new research is fundamentally shifting this perspective, suggesting that dissociation might be a vital, even necessary, component of ketamine's rapid antidepressant effects.

This episode unpacks a groundbreaking 2025 review paper by Bera and colleagues, revealing the intricate cortical mechanisms at play. At its core, ketamine doesn't just block NMDA receptors indiscriminately. Instead, it preferentially targets NMDA receptors on fast-spiking inhibitory neurons, specifically PV and SST cells—the "brakes" of the brain. This selective action leads to net disinhibition of pyramidal neurons, triggering a profound "switch" in brain activity: normally active neurons go silent, while previously dormant ones suddenly fire up. The total brain activity remains stable, but the internal conversation fundamentally changes, fragmenting normal circuit motifs and creating new patterns largely independent of external sensory input.

This internal reboot manifests as a slow, rhythmic "traveling wave" originating in the retrosplenial cortex (RSC). While the RSC maintains connection to ancient brain structures like the thalamus, it effectively uncouples from most of the conscious cortex. This "uncoupling" is the direct neurophysiological basis of detachment. Crucially, the HCN1 channels, acting as neuronal pacemakers, are also inhibited by ketamine, amplifying and stabilizing this new dissociative state. The acute dissociative experience, while brief, appears to be a necessary trigger for long-term brain repair. This happens through "ion trapping," where ketamine accumulates in acidic neuronal organelles, slowly releasing over time. This prolonged intracellular presence drives epigenetic changes—like increased histone acetylation and reduced DNA methylation on the BDNF gene—leading to new dendritic spines, synapses, and connections. Masking studies have further underscored the importance of conscious experience, showing that ketamine's antidepressant effects are blocked when dissociation is prevented by general anesthesia.

Resources:

Bera, K., Looger, L. L., Proekt, A., & Cichon, J. (2025). Cortical Mechanisms Contributing to Ketamine-Induced Dissociation. The Neuroscientist, 00(0), 1-17. https://doi.org/10.1177/10738584251403946

In this captivating episode, "Talking Ketamine" unpacks a groundbreaking paper by Sophie Holland that challenges our conventional understanding of ketamine, revealing it not as a single therapy, but a spectrum of modalities. The core tension lies in two distinct pathways: the high-dose "psychedelic" experience and the low-dose "psycholytic" approach. While chemically different from classic psychedelics, ketamine's subjective effects and its profound ability to induce neurogenesis and synaptogenesis—earning it the term "psychoplastogen" (think of it as rewiring and adding new rooms to your brain's house)—firmly establish its place in psychedelic medicine.

The psychedelic pathway, triggered by higher doses, induces intense altered states, often leading to ego dissolution and mystical experiences. This "reset button" effect is driven by a rapid, flood-like increase in glutamate transmission, distinct from traditional antidepressants. It offers swift, profound symptom reduction, particularly for severe, treatment-resistant conditions like depression, suicidality, and PTSD, by allowing emotional decoupling from trauma and enhancing cognitive flexibility. In contrast, the psycholytic pathway utilizes lower doses to subtly modulate consciousness, fostering a relaxed, trance-like state where patients remain connected to the present. Here, the goal shifts from ego dissolution to "ego loosening," reducing psychological defenses to facilitate deeper introspection and relational work within psychotherapy. This approach creates a safe space for gradual emotional exploration, enhancing the therapeutic process itself.

The episode emphasizes that understanding these dose-dependent differences is crucial for truly personalized medicine, balancing rapid relief with sustainable, integrated healing. It also highlights critical safety considerations, noting that lower-dose psycholytic approaches may carry a reduced risk of the severe urinary tract complications associated with chronic high-dose use. Beyond mental health, the psychoplastogenic power of ketamine opens exciting new frontiers in neurological recovery and even human optimization, with potential for enhancing creativity, problem-solving, and teamwork in healthy individuals through low-dose, integrated practices. This reimagining of ketamine calls for a radical shift in clinical practice, urging us to consider whether the most intense experience is always the best, or if the path that facilitates deeper relational work offers more lasting benefits.

Resources:

Holland, S. (2024). Ketamine Reimagined: Distinguishing Psychedelic and Psycholytic Modalities for Next-Generation Therapies. [Journal Information Not Available in Document], (N/A), N/A. [DOI Not Available in Document].

In this episode, we dive into a massive multicenter study involving over 74,000 hospital admissions across 44 children’s hospitals to explore the evolving role of ketamine in treating Sickle Cell Disease (SCD). For those living with SCD, "vaso-occlusive crises" are a brutal reality—rigid, sickle-shaped blood cells block blood flow like a dam, leading to oxygen deprivation and excruciating pain. While opioids have long been the first-line defense, many patients find their pain remains uncontrolled, leading to a dangerous cycle of tolerance and "opioid-induced hyperalgesia," where the medication actually makes the body more sensitive to pain.

Ketamine offers a way to break this cycle by acting as an "opioid-sparing adjunct." As discussed in the transcript, ketamine targets the NMDA receptor, which functions like a "volume dial" for pain signals. In cases of chronic, intense pain, this dial gets stuck at eleven—a process known as central sensitization. Ketamine steps in to turn off the amplifier, lowering the pain volume and preventing the nervous system from overreacting.

The most stunning revelation from this research is the power of timing. The study compared "early" ketamine administration (within the first three days) to "late" administration (day four or later). The results were night and day: patients who received ketamine early saw their median hospital stays drop from 12 days to just 6, and their need for IV opioids fell from 9 days to 4. Despite these compelling numbers, institutional "red tape" and lingering stigma remain significant barriers to adoption, raising critical questions about how we can streamline care for our most vulnerable patients.

Resources:

Jenkins, A. M., Hendry, E., Power-Hays, A., Valentino, M., Hall, M., Kyler, K. E., Antoon, J. W., Tang Girdwood, S., Goldman, J. L., Morel, A. N., Savage, T. J., Orth, L. E., & Archer, N. M. (2025). Increasing ketamine administration in children’s hospitals for youth with sickle cell disease. Blood Advances. https://doi.org/10.1182/bloodadvances.2025016826.